Alkermes Pharma Ireland Limited

Flak Pharma International, Ltd.

Kenneth Iain Cumming

Rajeev A Jain

Maurice Joseph Anthony Clancy

Janet Elizabeth Codd

Stephen B Ruddy

Gary G Liversidge

John G Devane

Jon Swanson

Robert Hontz

Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.

Controlled-release nanoparticulate compositions

Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.

Rapidly disintegrating solid oral dosage form

Growing community of inventors

Essex, United Kingdom

Kenneth Iain Cumming